Welcome to Northwestern Medicine Antimicrobial Stewardship 

NM COVID-19 Resources

Please note: If using these resources, please understand this information will continue to change as the COVID-19 situation evolves in Chicago and across the United States.
Last updated: 1/3/22

Northwestern Medicine COVID-19 Treatment Options

• NM COVID-19 Clinical Pathway - ED, Floor, & ICU Patients
• NM COVID-19 Outpatient Therapy Guidance - Ambulatory
• ​NM COVID-19 Clinical Trials​

COVID-19 Treatment Guidelines and Resources

• ​NIH COVID-19 Treatment Guidelines
• ​IDSA COVID-19 Treatment Guidelines
• Sotrovimab EUA Information​
• Paxlovid EUA Information for Healthcare Providers
  • Patient EUA Fact Sheet
  • Drug-Drug Interaction Checker - Univ of Liverpool​
• Molnupiravir EUA Information for Healthcare Providers
  • ​Patient EUA Fact Sheet
• Evusheld Pre-Exposure Prophylaxis EUA Information for Healthcare Providers
• IL-6 Inhibitor COVID-19 Treatment Allocation Plan

No longer recommended due to increased prevalence of Omicron variant (as of 12.22.2021)

• Casirivimab/Imdevimab EUA Information
• ​Bamlanivimab/Etesevimab EUA Information​

---

Our Mission

To ensure that our patients receive the safest and most effective antimicrobial therapy for their infection while preserving and protecting the effectiveness of these endangered resources for future patients.

---

---

Clinician Antimicrobial Stewardship Training Resources

---

CDC Global Antimicrobial Resistance Challenge

"Northwestern Medicine, an integrated academic health system in the Chicago area with 4,000 physicians and 30,000 employees caring for over 1.1 million patients, is committed to improving antibiotic use to ensure that these important medications remain effective treatment options. The Antimicrobial Stewardship Quality Committee commits to using local and CDC data to reduce unnecessary antibiotic use across their system. They also commit to increased use of penicillin allergy testing to remove misdiagnoses and decrease the use of broader-spectrum antibiotics. Utilizing both of these interventions will be aimed at reducing overly broad spectrum antibiotic use and emphasize their strong commitment to better patient care and combating antibiotic resistance."

See "Northwestern Medicine" on the CDC AMR Challenge Website

---

System P&T Updates

IV Metronidazole Alternatives

C. difficile Infection Treatment Guidelines for Hospitalized Patients

Vancomycin (IV) Dosing and Monitoring Guideline

---

C. difficile Diagnostic Algorithm

Northwestern Medicine has launched an updated Clostridioides difficile diagnostic algorithm across the healthcare system. Below are clinical decision support tools to guide providers through this transition.

FAQs: NM Diagnosis and Treatment of C. difficile Infection

C. difficile Infection Testing Algorithm: PCR/Reflex Toxin EIA

NMH Go-Live: 5/4/2021
All other sites, except Northwest Region: 7/24/2021
​*subject to change, will update periodically

---

Oral Cephalosporin Recommendations

Oral Cephalosporin and Acid-Suppression Therapy Drug Interaction Guidance Document​

---

Culture Decision Algorithms

Culturing Decision Trees - Urine Cultures
Culturing Decision Trees - Blood Cultures

---

​Safety Update: Fluoroquinolones

• FDA Warning For Fluoroquinolone-Associated Aortic Dissections/Ruptures​​
• 10 Ways to Reduce Fluoroquinolone Prescribing in the Hospital
• 10 Ways to Reduce Fluoroquinolone Prescribing in Ambulatory Care

---

NMH Allergy Toolkit

Risk Assessment and Clinical Pathway
Graded Challenge Guidance Document
Provider Education: Penicillin Allergy
Cross Reactivity Chart: Beta-lactams

---

Follow us on Twitter!
@NM_IDSteward

Tweets by NM_IDSteward

---